# Azelis account plan

> Azelis is an Antwerp-based distributor of speciality chemicals and food ingredients with 65,000+ customers: EUR 4,111m FY2025 revenue.

## At a glance

Azelis Group NV, headquartered in Antwerp and listed on Euronext Brussels (AZE, BEL20), distributes speciality chemicals and food ingredients and acts as an outsourced sales, marketing and technical arm for producers (its principals). It serves 65,000+ customers through 2,800+ principal relationships and 70+ application and formulating labs, and is present in 64 countries. FY2025 revenue was EUR 4,111m (-2.4%, +1.3% in constant currency), adjusted EBITA EUR 411m (10.0% margin) and net profit EUR 113m, with 4,189 FTEs. Life Sciences generated EUR 2,609m of revenue and Industrial Chemicals EUR 1,502m.

## Business units

- **EMEA** (45.5% of FY2025 revenue (EUR 1,871m)): The largest region, with 1,941 employees, 63 offices and 33 labs, led by CEO EMEA Evy Hellinckx. FY2025 revenue grew 4.4%, all from acquisitions (Solchem, ACEF, Distona); in Q3 2026 revenue was EUR 499m (+8.1%), driven by Industrial Chemicals (+29.1%) on CASE and Lubricants & Metal Working Fluids, while Life Sciences declined.
- **Americas** (34.9% of FY2025 revenue (EUR 1,435m)): 1,094 employees, 23 offices and 19 labs, led by CEO Americas Todd Cottrell. FY2025 revenue fell 6.6% with weak CASE demand and margin pressure in Latin America; Q3 2026 revenue rose 8.0% organically to EUR 405m. A EUR 350m non-cash goodwill impairment was booked in Q3 2026 on Americas acquisitions made in 2021-2023.
- **Asia Pacific** (19.6% of FY2025 revenue (EUR 805m)): 986 employees, 27 offices and 23 labs, led by CEO Asia Pacific Benoit Fritz since September 2025. FY2025 revenue fell 9.0% on Chinese oversupply and a decommoditisation programme costing over EUR 13m; the S. Amit acquisition strengthened India. It returned to strong organic growth in 2026, with Q3 revenue of EUR 218m (+10.2%).

## Strategic priorities

- **Market segment leadership**: Azelis wants to be the reference partner in defined segments of Life Sciences and Industrial Chemicals, using cross-selling, smart pricing and a curated portfolio; a Group Commercial Excellence Director was appointed in 2025.
- **Active consolidator**: Since 2017 Azelis has made over 60 acquisitions; the four 2025 bolt-ons (Solchem, S. Amit, ACEF, Distona) add over EUR 110.0m of annual revenue. The CEO says Azelis does not want to overpay while sellers keep high expectations.
- **One agile Azelis and AI-enabled back offices**: Local organisations run on one ERP, one CRM and a central data lake; shared service centres are rolled out in each region, notably for finance, and over 200 customer portals are live.
- **2026-2031 medium-term targets**: Announced on 29 September 2026: mid to high single-digit annual gross profit growth, high single-digit annual adjusted EBITA growth, a doubling of EPS by 2031 and ROCE > 11.5% by 2031.
- **Deleveraging and cash discipline**: Leverage of 3.3x at end-2025 is "on the high side"; management aims not to be too far from 3.0 and to keep the BB+ rating, after delivering EUR 20 million of cost savings.

## Latest results

Q3 2026 revenue was EUR 1,122m, +8.5% in constant currency with organic growth of 8.2%, and nine-month revenue EUR 3,288m (+4.9%). Industrial Chemicals drove the quarter with revenue of EUR 451m (+21.0%), while Life Sciences grew 1.5% to EUR 671m; all regions grew. Adjusted EBITA rose 14.6% to EUR 114m (10.2% margin). Inventories rose to support demand (DIO 59 days), cutting free cash flow to EUR 67m, and leverage stood at 3.46x after a EUR 350m non-cash goodwill impairment in the Americas. Azelis remains confident of positive organic adjusted EBITA growth for full-year 2026.

## Investments and deals

- **2025 bolt-on acquisitions**: Solchem Nature (Spain, nutraceuticals), S. Amit Group (India, performance chemicals), ACEF (Italy, Personal Care) and Distona (Switzerland, industrial chemicals) added EUR 61.1 million of revenue in 2025; 2025 M&A cash-out was about EUR 230 million including deferred payments.
- **Bond refinancing**: In March 2026 a EUR 400 million 4.125% bond due 2031 replaced the 5.75% bond due 2028, saving about EUR 6.5 million of coupon a year.
- **Vogler Ingredients buy-out**: In April 2026 Azelis bought out the non-controlling interests in Vogler Ingredients in Brazil.
- **Digital and lab network**: Azelis runs 70+ application and formulating labs, is rolling out version 3.0 of its principal portal and is embedding AI in most processes; holding company costs rose on higher IT investments.

## Challenges and risks

- **Volatile end-market demand**: Tariff uncertainty, customers unwilling to build stock and the Middle East conflict keep volatility high; EMEA Life Sciences and Flavours & Fragrances stayed soft in 2026.
- **Chinese competition on semi-commodities**: Increased supply from China pressures the 15%-20% semi-commodity part of the portfolio, especially in Southeast Asia, Africa, Brazil and Mexico.
- **Leverage and working capital**: Net debt was EUR 1,640m and leverage 3.46x in Q3 2026; working capital rose to 17.2% of revenue and nine-month free cash flow fell 35.2%.
- **Dependence on principals**: The top ten principals supplied 33.3% of 2025 revenue, and some principals take customers back in-house or rationalise distributor networks.
- **Cybersecurity**: Cybersecurity is the first of the six top business risks named in the 2025 Integrated Report.

## What leadership says

> "Many of the green shoots we saw earlier this year have taken root, despite continued market volatility." — Anna Bertona, Group CEO, Q3 2026 results release, 2026-10-22

> "This is the time to make bold actions that will pay off when the cycle turns, and the cycle will turn." — Anna Bertona, Group CEO, Full-year 2025 results call, 2026-02-19

> "We are operating in an environment where volatility has become the norm rather than the exception." — Anna Bertona, Group CEO, H1 2026 results call, 2026-07-30

> "In any given year, our net wins are always more than our losses. Also this year that's the case." — Anna Bertona, Group CEO, H1 2026 results call, 2026-07-30, on principal relationships


## Where a supplier can help

- **Shared services and finance automation**: Building AI-enabled back offices and regional shared service centres (one agile Azelis priority) creates demand for finance automation, process mining and AI tooling.
- **Inventory and working capital tools**: With DIO back up to 59 days and working capital at 17.2% of revenue (leverage challenge), demand planning, inventory optimisation and receivables tools support the deleveraging goal.
- **Acquisition integration**: As an active consolidator integrating each acquisition onto one ERP and CRM, Azelis needs data migration, integration and change management partners.
- **Cybersecurity**: Cybersecurity is the top named risk for a group running customer and principal portals on a single platform, opening the door to security and resilience providers.
- **Lab and formulation capabilities**: The 70+ labs and the push to increase specialties in APAC (segment leadership priority) point to lab equipment, formulation software and regulatory data services.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Integrated Report 2025](https://www.azelis.com/sites/default/files/uploads/Azelis%20Group%20NV%20-%20Integrated%20Report%202025.pdf)

Annual report · 2026-02-19

- Azelis is a Belgian (Antwerp) listed distributor and "innovation service provider" for speciality chemicals and food ingredients: 65,000+ customers, 2,800+ principal relationships, 70+ application and formulating labs, listed on Euronext Brussels (AZE, BEL20).
- FY2025 revenue EUR 4.1bn (EUR 4,111m), down 2.4% (+1.3% in constant currency): 1.6% organic contraction, 3.8% F/X headwind, 2.9% contribution from acquisitions. Life Sciences EUR 2.6bn, Industrial Chemicals EUR 1.5bn.
- Profitability fell: gross profit EUR 968m (margin 23.6%, -91 bp), adjusted EBITA EUR 411m (-12.7%, margin 10.0%), net profit EUR 113m (-40.1%), EPS EUR 0.46; effective tax rate 35.3%.
- Cash was the bright spot: free cash flow EUR 442m (+29.2%), cash conversion 106%, NWC/revenue 14.1% (from 15.9%), DIO cut from 57 to 51 days; but leverage rose to 3.3x (2.9x in 2024) on net debt of EUR 1.6bn.
- Regions: EMEA 45.5% of revenue (EUR 1,871m, +4.4% thanks to M&A), Americas 34.9% (EUR 1,435m, -6.6%), Asia Pacific 19.6% (EUR 805m, -9.0%, hit by Chinese oversupply and a decommoditisation programme costing over EUR 13m).
- Strategy unchanged: three pillars (market segment leadership, an active consolidator, one agile Azelis) and three accelerators (innovation, sustainability, digitalisation). Four bolt-ons in 2025 (Solchem, S. Amit, ACEF, Distona), together over EUR 110.0m of annual revenue; EUR 20 million of cost savings delivered.
- Capital allocation: organic investment, dividends (EUR 0.226 per share proposed), prudent de-leveraging to keep the BB+ rating, then value-accretive acquisitions.
- Leadership: CEO Anna Bertona, Chair Kare Schultz; CFO Thijs Bakker left at end-2025, replaced by Boris Cambon-Lalanne from January 2026; EQT fell below 10% and its two directors step down.
- Main risks: cybersecurity, dependence on strategic principals (top ten principals = 33.3% of revenue), foreign currency, financial uncertainty, supplier/distributor consolidation, inventory management.

### [Interim financial report for the first six months of 2026](https://www.azelis.com/sites/default/files/uploads/Azelis%20Group%20NV%20-%20Interim%20financial%20report%20for%20the%20first%20six%20months%20of%202026%20ENG_FINAL.pdf)

Interim report · 2026-07-30

- H1 2026 revenue EUR 2,166m (EUR 2.2bn), +3.2% in constant currency: organic +0.3%, acquisitions +2.9%. Q2 revenue EUR 1.1bn, +6.3% in constant currency, with organic growth of 3.9% after four quarters of decline.
- Gross profit EUR 524m, margin 24.2% (+28 bp in constant currency), helped by pricing momentum and a favourable inventory position.
- Adjusted EBITA EUR 233m (+2.6% in constant currency), margin 10.7%; Q2 adjusted EBITA EUR 128m, +12.7% in constant currency, margin 11.4%.
- Net profit EUR 86m, cash EPS EUR 0.52; free cash flow EUR 122m (-19.0%), FCF conversion 52.3% as working capital rose to 16.0% of revenue.
- Net debt stable at EUR 1.6bn, leverage 3.4x; March 2026 refinancing: EUR 400m 4.125% bond due 2031 replaced the 5.75% bond due 2028.
- Regions: EMEA EUR 990m (organic -4.6%, acquisitions +6.3%), Americas EUR 748m (+2.3%, all organic), Asia Pacific EUR 428m (+8.2%, all organic; Q2 organic +12.7%).
- Outlook: aim for positive adjusted EBITA growth for full-year 2026 assuming no significant market change; Middle East conflict keeps volatility high. MSCI ESG upgraded to AAA; SBTi validated targets in May.

### [Q3 2026 results: Organic growth momentum continued in the third quarter](https://www.azelis.com/sites/default/files/uploads/Azelis%20Group%20NV%20-%20Q3%202026%20Trading%20Update%20EN.pdf)

Interim report · 2026-10-22

- Q3 2026 revenue EUR 1,122m (EUR 1.1bn), +8.5% in constant currency, with organic growth of 8.2%; nine-month revenue EUR 3,288m (+4.9%).
- Industrial Chemicals drove the quarter: revenue EUR 451m, +21.0% (organic 20.2%), led by CASE and Lubricants & Metal Working Fluids in EMEA; Life Sciences EUR 671m, +1.5%.
- Adjusted EBITA EUR 114m, +14.6% (organic 14.3%), margin 10.2% (+54 bp); gross margin 23.4%.
- All regions grew: EMEA EUR 499m (+8.1%), Americas EUR 405m (+8.0%), Asia Pacific EUR 218m (+10.2%), the last two entirely organic.
- A EUR 350m non-cash goodwill impairment was booked in the Americas for acquisitions made in 2021-2023.
- Free cash flow EUR 67m (conversion 58.6%) as inventories rose (DIO 59 days); net debt EUR 1.6bn, leverage 3.46x.
- Medium-term targets announced 29 September for 2026-2031: mid to high single-digit annual gross profit growth, high single-digit annual adjusted EBITA growth, doubling of EPS by 2031, ROCE > 11.5% by 2031.
- Outlook: confident of positive organic adjusted EBITA growth for full-year 2026.

### [Azelis full-year 2025 results call (transcript)](https://finance.biggo.com/quote/AZLGF/earnings-call/US_AZLGF_2026-02-19)

Executive talk · Anna Bertona, Group CEO · 2026-02-19

- Anna Bertona (CEO) and new CFO Boris Cambon-Lalanne presented FY2025 on 19 February 2026: revenue EUR 4.1bn, free cash flow EUR 442 million, cash conversion 106%, four bolt-on acquisitions.
- Bertona: "the challenges that the chemical distribution market is going through are temporary"; near-term focus on "cost, working capital, and cash optimization", while being ready "to capture organic growth, and to lead consolidation".
- Strategy: leadership in focus end markets, consolidation (with customers and principals as well as M&A), and "one agile Azelis"; a global commercial director appointed; first global customer satisfaction survey (4,000+ customers, score 8.3 on 10).
- Digital and AI: over 200 customer portals live, version 3.0 of the principal portal rolling out, AI being embedded in most processes, shared service centres and "AI-enabled back offices".
- M&A paced: sellers still have high expectations; Azelis has paid "high single digits" multiples in the past and does not want to overpay. 2025 M&A cash-out was about EUR 230 million including about EUR 100 million of deferred payments.
- Balance sheet: leverage 3.3x is "on the high side"; direction of travel is not to be "too far away from 3.0"; BB+ rating to keep; buybacks not ruled out.
- On Chinese competition: pressure on the 15%-20% semi-commodity part of the portfolio, not intensifying; Azelis is "agnostic" on where principals come from.
- Principal behaviour: some principals cut sales staff and give more to distribution, others take customers back ("short-term margin grab"), usually reversed within one or two years.

### [Azelis H1 2026 results call (transcript)](https://finance.biggo.com/quote/AZLGF/earnings-call/US_AZLGF_2026-07-30)

Executive talk · Anna Bertona, Group CEO · 2026-07-30

- Anna Bertona (CEO) and CFO Boris Cambon-Lalanne presented H1 2026 results on 30 July 2026: first positive group organic revenue growth "in more than a year", with 4% organic growth in Q2 reversing the Q1 decline.
- H1 revenue EUR 2.2 billion, more than 3% higher in constant currency; adjusted EBITA EUR 233 million; Q2 adjusted EBITA up 12% year on year and 23% sequentially.
- APAC was the main driver (organic growth accelerating from 4% in Q1 to 13% in Q2); Americas Life Sciences recovering (Personal Care, food); EMEA CASE recovering but EMEA Life Sciences soft, Flavours & Fragrances under price pressure and agri hit by dry weather.
- Guidance: aim for positive EBITA growth for full-year 2026, based on the order book, assuming current market conditions continue; pre-buying "very limited".
- Inventory gains from rising prices (stock of about 2 to 3 months) will ease; no large principal price moves expected.
- CFO: normalised for one-offs and FX, H1 EBITA growth would be +12%; EUR 11 million of structural savings in H1; refinancing saves EUR 6.5 million a year; factoring kept at about 25% of receivables.
- Principals: "our net wins are always more than our losses"; outsourcing trend continues.

## Questions about Azelis

### What does Azelis do?

Azelis distributes speciality chemicals and food ingredients, co-develops formulations with customers in its labs and acts as an outsourced sales and marketing arm for producers across Life Sciences and Industrial Chemicals.

### What is Azelis's revenue?

FY2025 revenue was EUR 4,111m with adjusted EBITA of EUR 411m. Nine-month 2026 revenue was EUR 3,288m, up 4.9% in constant currency.

### How many employees does Azelis have?

Azelis had 4,189 FTEs at the end of 2025 and describes itself as having over 4,100 employees in 64 countries.

### What is Azelis's strategy?

The strategy rests on market segment leadership, an active role in consolidation and one agile Azelis platform, supported by innovation, sustainability and digitalisation. Its 2026-2031 targets include doubling EPS by 2031.

### Who leads Azelis?

Anna Bertona has been CEO since 1 January 2024, Kare Schultz chairs the board, and Boris Cambon-Lalanne became Group CFO in January 2026.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
